Vektor Medical builds vMap, an AI-based, non-invasive arrhythmia analysis platform that uses a 12-lead ECG to localize arrhythmia sources and provide actionable insights to electrophysiologists. vMap is FDA-cleared and is being used by leading EPs in the U.S. to streamline ablation procedures and improve patient outcomes. The company plans to expand commercialization efforts, increase clinical support, and drive additional clinical studies to demonstrate clinical impact. Vektor is also pursuing reimbursement efforts to broaden access to the technology. The company is headquartered in San Diego. Its recent $16 million Series A will fund these commercialization and clinical initiatives.

Total raised

$16M

Funding rounds

1

Latest round

Series A

Latest activity

Feb 2024